NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$27.38 +0.32 (+1.18 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$27.06
Today's Range$26.68 - $27.76
52-Week Range$13.50 - $44.00
Volume572,200 shs
Average Volume830,448 shs
Market Capitalization$730.13 million
P/E Ratio-6.90
Dividend YieldN/A
Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.63
Current Ratio9.85
Quick Ratio9.73


Trailing P/E Ratio-6.90
Forward P/E Ratio-4.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$570,000.00
Price / Sales1,295.99
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book9.44


EPS (Most Recent Fiscal Year)($3.97)
Net Income$-89,490,000.00
Net Margins-3,470.97%
Return on Equity-101.94%
Return on Assets-56.21%


Outstanding Shares26,980,000
Market Cap$730.13

The Truth About Cryptocurrencies

Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) released its quarterly earnings results on Thursday, May, 3rd. The specialty pharmaceutical company reported ($1.35) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.02. The specialty pharmaceutical company had revenue of $2.55 million for the quarter, compared to analysts' expectations of $1.71 million. Adamas Pharmaceuticals had a negative return on equity of 101.94% and a negative net margin of 3,470.97%. View Adamas Pharmaceuticals' Earnings History.

What price target have analysts set for ADMS?

12 brokerages have issued 1-year price targets for Adamas Pharmaceuticals' stock. Their forecasts range from $31.00 to $55.00. On average, they expect Adamas Pharmaceuticals' share price to reach $43.2222 in the next twelve months. This suggests a possible upside of 57.9% from the stock's current price. View Analyst Ratings for Adamas Pharmaceuticals.

What is the consensus analysts' recommendation for Adamas Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Adamas Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We have utilized a discounted cash flow (DCF)-based approach to derive a composite valuation assessment of Adamas, which ascribes value to the company’s two principal product opportunities— GOCOVRI and ADS-5102—while also accounting for the token value provided by the royalty stream from Allergan plc on two other controlled-release products, for treatment of moderate-to-severe Alzheimer’s disease (AD)." (7/16/2018)
  • 2. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (5/9/2018)
  • 3. Mizuho analysts commented, "We believe Adamas is building a solid case for the importance of Gocovri within the Parkinson’s treatment paradigm, thereby increasing the company’s attractiveness as a takeout candidate longer-term. We reiterate our Buy rating and $49 PT." (4/20/2018)

Who are some of Adamas Pharmaceuticals' key competitors?

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the folowing people:
  • Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 54)
  • Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 48)
  • Dr. Rajiv Patni, Chief Medical Officer (Age 49)
  • Mr. Alfred G. Merriweather, Chief Financial Officer (Age 64)
  • Mr. Richard A. King, Chief Operating Officer (Age 53)

Has Adamas Pharmaceuticals been receiving favorable news coverage?

News headlines about ADMS stock have trended somewhat negative on Monday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adamas Pharmaceuticals earned a news sentiment score of -0.01 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 45.76 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BROADFIN CAPITAL, LLC (5.37%), Fisher Asset Management LLC (0.54%), Verde Servicos Internacionais S.A. (0.09%) and Hartwell J M Limited Partnership (0.06%). Company insiders that own Adamas Pharmaceuticals stock include Christopher B Prentiss, Great Point Partners Llc, Gregory T Went, Ix Lp Mdv, Jennifer J Rhodes, Rajiv Patni, Richard King, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.

Which major investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Hartwell J M Limited Partnership. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Insider Buying and Selling for Adamas Pharmaceuticals.

Which major investors are buying Adamas Pharmaceuticals stock?

ADMS stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Verde Servicos Internacionais S.A.. Company insiders that have bought Adamas Pharmaceuticals stock in the last two years include Ix Lp Mdv and William W Ericson. View Insider Buying and Selling for Adamas Pharmaceuticals.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $27.37.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $730.13 million and generates $570,000.00 in revenue each year. The specialty pharmaceutical company earns $-89,490,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. Adamas Pharmaceuticals employs 147 workers across the globe.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 750, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]

MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Featured Article: Analyst Ratings

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.